The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Men and women aged 18 years or older at the time of signing informed consent.
Able and willing to sign the informed consent form (ICF).
Ability to comply with the trial protocol.
Histologically confirmed Marginal Zone Lymphoma (MZL) of Extranodal Marginal Zone Lymphoma (EMZL), Nodal Marginal Zone Lymphoma (NMZL) and Splenic Marginal Zone Lymphoma (SMZL) subtypes presenting with stage I-IV disease.
Threatened extranodal organ function, especially for extranodal MZL
Involvement of ≥3 nodal sites, each with diameter of ≥3 cm
Any nodal or extranodal tumor mass with a diameter of ≥5 cm
B symptoms (fever ≥38 degrees Celsius of unclear etiology, night sweats, weight loss >10% within the prior 6 months) or other symptoms attributed to disease or specific organ involvement.
Izidore Lossos, MD
Lead sponsor
University of Miami
Sponsor institution
Genmab
Collaborator
AbbVie
Collaborator